Literature DB >> 24706829

Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain.

Mark W Richards1, Edward W P Law, La'Verne P Rennalls, Sara Busacca, Laura O'Regan, Andrew M Fry, Dean A Fennell, Richard Bayliss.   

Abstract

Proteins of the echinoderm microtubule-associated protein (EMAP)-like (EML) family contribute to formation of the mitotic spindle and interphase microtubule network. They contain a unique hydrophobic EML protein (HELP) motif and a variable number of WD40 repeats. Recurrent gene rearrangements in nonsmall cell lung cancer fuse EML4 to anaplastic lymphoma kinase (ALK), causing expression of several fusion oncoprotein variants. We have determined a 2.6-Å crystal structure of the representative ∼70-kDa core of EML1, revealing an intimately associated pair of β-propellers, which we term a TAPE (tandem atypical propeller in EMLs) domain. One propeller is highly atypical, having a discontinuous subdomain unrelated to a WD40 motif in place of one of its blades. This unexpected feature shows how a propeller structure can be assembled from subdomains with distinct folds. The HELP motif is not an independent domain but forms part of the hydrophobic core that joins the two β-propellers. The TAPE domain binds α/β-tubulin via its conserved, concave surface, including part of the atypical blade. Mapping the characteristic breakpoints of each EML4-ALK variant onto our structure indicates that the EML4 TAPE domain is truncated in many variants in a manner likely to make the fusion protein structurally unstable. We found that the heat shock protein 90 (Hsp90) inhibitor ganetespib induced degradation of these variants whereas others lacking a partial TAPE domain were resistant in both overexpression models and patient-derived cell lines. The Hsp90-sensitive EML4-ALK variants are exceptions to the rule that oncogenic fusion proteins involve breakpoints in disordered regions of both partners.

Entities:  

Keywords:  stratified medicine; structural biology

Mesh:

Substances:

Year:  2014        PMID: 24706829      PMCID: PMC3986153          DOI: 10.1073/pnas.1322892111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  The CCP4 suite: programs for protein crystallography.

Authors: 
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1994-09-01

2.  EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

Authors:  Young Lim Choi; Manabu Soda; Yoshihiro Yamashita; Toshihide Ueno; Junpei Takashima; Takahiro Nakajima; Yasushi Yatabe; Kengo Takeuchi; Toru Hamada; Hidenori Haruta; Yuichi Ishikawa; Hideki Kimura; Tetsuya Mitsudomi; Yoshiro Tanio; Hiroyuki Mano
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

3.  The human EMAP-like protein-70 (ELP70) is a microtubule destabilizer that localizes to the mitotic apparatus.

Authors:  Bernd Eichenmuller; Patrick Everley; Jean Palange; Denise Lepley; Kathy A Suprenant
Journal:  J Biol Chem       Date:  2001-11-02       Impact factor: 5.157

4.  Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

Authors:  Ryohei Katayama; Tahsin M Khan; Cyril Benes; Eugene Lifshits; Hiromichi Ebi; Victor M Rivera; William C Shakespeare; A John Iafrate; Jeffrey A Engelman; Alice T Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-18       Impact factor: 11.205

5.  Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.

Authors:  Zhao Chen; Takaaki Sasaki; Xiaohong Tan; Julian Carretero; Takeshi Shimamura; Danan Li; Chunxiao Xu; Yuchuan Wang; Guillaume O Adelmant; Marzia Capelletti; Hyun Joo Lee; Scott J Rodig; Christa Borgman; Seung-Il Park; Hyeong Ryul Kim; Robert Padera; Jarrod A Marto; Nathanael S Gray; Andrew L Kung; Geoffrey I Shapiro; Pasi A Jänne; Kwok-Kin Wong
Journal:  Cancer Res       Date:  2010-10-15       Impact factor: 12.701

6.  Intrinsic structural disorder confers cellular viability on oncogenic fusion proteins.

Authors:  Hedi Hegyi; László Buday; Peter Tompa
Journal:  PLoS Comput Biol       Date:  2009-10-30       Impact factor: 4.475

7.  The structure of Aip1p, a WD repeat protein that regulates Cofilin-mediated actin depolymerization.

Authors:  Walter C Voegtli; A Yarrow Madrona; David K Wilson
Journal:  J Biol Chem       Date:  2003-06-14       Impact factor: 5.157

8.  The C. elegans EMAP-like protein, ELP-1 is required for touch sensation and associates with microtubules and adhesion complexes.

Authors:  Jennifer L Hueston; Gina Purinton Herren; Juan G Cueva; Matthew Buechner; Erik A Lundquist; Miriam B Goodman; Kathy A Suprenant
Journal:  BMC Dev Biol       Date:  2008-11-17       Impact factor: 1.978

9.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21

10.  EMAP, an echinoderm microtubule-associated protein found in microtubule-ribosome complexes.

Authors:  K A Suprenant; K Dean; J McKee; S Hake
Journal:  J Cell Sci       Date:  1993-02       Impact factor: 5.285

View more
  41 in total

Review 1.  ALK alterations and inhibition in lung cancer.

Authors:  Tri Le; David E Gerber
Journal:  Semin Cancer Biol       Date:  2016-09-13       Impact factor: 15.707

2.  Mutations in Eml1 lead to ectopic progenitors and neuronal heterotopia in mouse and human.

Authors:  Michel Kielar; Françoise Phan Dinh Tuy; Sara Bizzotto; Cécile Lebrand; Camino de Juan Romero; Karine Poirier; Renske Oegema; Grazia Maria Mancini; Nadia Bahi-Buisson; Robert Olaso; Anne-Gaëlle Le Moing; Katia Boutourlinsky; Dominique Boucher; Wassila Carpentier; Patrick Berquin; Jean-François Deleuze; Richard Belvindrah; Victor Borrell; Egbert Welker; Jamel Chelly; Alexandre Croquelois; Fiona Francis
Journal:  Nat Neurosci       Date:  2014-05-25       Impact factor: 24.884

3.  EML4-ALK V3, treatment resistance, and survival: refining the diagnosis of ALK+ NSCLC.

Authors:  Petros Christopoulos; Martina Kirchner; Volker Endris; Albrecht Stenzinger; Michael Thomas
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

Review 4.  Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.

Authors:  Ryohei Katayama; Christine M Lovly; Alice T Shaw
Journal:  Clin Cancer Res       Date:  2015-05-15       Impact factor: 12.531

Review 5.  JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships.

Authors:  András Zeke; Mariya Misheva; Attila Reményi; Marie A Bogoyevitch
Journal:  Microbiol Mol Biol Rev       Date:  2016-07-27       Impact factor: 11.056

Review 6.  Kinase inhibitors: the road ahead.

Authors:  Fleur M Ferguson; Nathanael S Gray
Journal:  Nat Rev Drug Discov       Date:  2018-03-16       Impact factor: 84.694

7.  Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

Authors:  Jessica J Lin; Viola W Zhu; Satoshi Yoda; Beow Y Yeap; Alexa B Schrock; Ibiayi Dagogo-Jack; Nicholas A Jessop; Ginger Y Jiang; Long P Le; Kyle Gowen; Philip J Stephens; Jeffrey S Ross; Siraj M Ali; Vincent A Miller; Melissa L Johnson; Christine M Lovly; Aaron N Hata; Justin F Gainor; Anthony J Iafrate; Alice T Shaw; Sai-Hong Ignatius Ou
Journal:  J Clin Oncol       Date:  2018-01-26       Impact factor: 44.544

8.  RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.

Authors:  Gorjan Hrustanovic; Victor Olivas; Evangelos Pazarentzos; Asmin Tulpule; Saurabh Asthana; Collin M Blakely; Ross A Okimoto; Luping Lin; Dana S Neel; Amit Sabnis; Jennifer Flanagan; Elton Chan; Marileila Varella-Garcia; Dara L Aisner; Aria Vaishnavi; Sai-Hong I Ou; Eric A Collisson; Eiki Ichihara; Philip C Mack; Christine M Lovly; Niki Karachaliou; Rafael Rosell; Jonathan W Riess; Robert C Doebele; Trever G Bivona
Journal:  Nat Med       Date:  2015-08-24       Impact factor: 53.440

9.  ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.

Authors:  Merrida A Childress; Stephen M Himmelberg; Huiqin Chen; Wanleng Deng; Michael A Davies; Christine M Lovly
Journal:  Mol Cancer Res       Date:  2018-07-12       Impact factor: 5.852

10.  EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7.

Authors:  Laura O'Regan; Giancarlo Barone; Rozita Adib; Chang Gok Woo; Hui Jeong Jeong; Emily L Richardson; Mark W Richards; Patricia A J Muller; Spencer J Collis; Dean A Fennell; Jene Choi; Richard Bayliss; Andrew M Fry
Journal:  J Cell Sci       Date:  2020-05-11       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.